1. DARE to PLAY™ is the first sildenafil cream for women. 2. Commercial launch addresses a major gap in women's sexual health. 3. Available in select states as a compounded product through a 503B facility. 4. Clinical studies validate its effectiveness in increasing genital blood flow. 5. Market potential includes 20 million women with genital arousal issues.
FAQ
Why Bullish?
The introduction of a unique, evidence-backed product may significantly enhance DARE's market presence, akin to the impact of Viagra for men. Historical breakthroughs in women's health often lead to increased investor interest and stock price appreciation.
How important is it?
This announcement highlights a pivotal moment for DARE, establishing its first significant product in a large market. A product launch catering to an underserved demographic is likely to attract attention and bolster investor confidence.
Why Long Term?
As DARE to PLAY™ gains traction in the market, its long-term commercial potential looks promising. Increased awareness and subsequent sales may take time, but sustained demand could steadily uplift stock performance.
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription
Daré Bioscience, Inc. (NASDAQ: DARE), a leading health biotech firm focused on women's health, has announced that its innovative product, DARE to PLAY™ Sildenafil Cream, is now available for pre-order by prescription in select states. This first-of-its-kind topical arousal cream offers a significant advancement in women’s sexual health, aiming to alleviate issues of sexual arousal through scientifically-backed formulation.
Overview of DARE to PLAY™ Sildenafil Cream
DARE to PLAY™ is a proprietary, non-hormonal topical cream specifically designed for women. Clinical studies have shown it can increase genital blood flow within 10–15 minutes, enhancing arousal sensations based on validated endpoints. This product represents a significant step towards addressing the persistent gender gap in sexual health treatments.
Commercial Rollout and Availability
The cream will initially be available through a 503B outsourcing facility, highlighting its production under current Good Manufacturing Practices (cGMP) and clinical data support. This marks the first opportunity for women to access a topical sildenafil formulation that is not only evidence-based but also manufactured under stringent quality standards.
Healthcare providers in select states such as Connecticut, Florida, Indiana, Missouri, New Hampshire, New Jersey, Oregon, Pennsylvania, Rhode Island, and Utah are currently able to prescribe DARE to PLAY™. Orders will ship within 45 days during the pre-order phase.
Scientific Background and Validation
Using the same active ingredient as Viagra®, sildenafil, DARE to PLAY™ works at the local level to enhance natural arousal responses, avoiding systemic effects. Unlike other products that rely on marketing and anecdotal reviews, DARE to PLAY™ is backed by:
- Toxicology studies covering various aspects of women's health.
- Multiple clinical trials, including a randomized placebo-controlled study with 200 participants.
- Peer-reviewed research published in reputable medical journals.
As stated by Dr. Irwin Goldstein, a sexual health expert, “The need for research-backed solutions has never been greater.”
Market Opportunity for Women's Sexual Health
An estimated 20 million women in the United States face challenges related to genital arousal. The lack of FDA-approved therapeutics leaves a gap that DARE to PLAY™ seeks to fill, providing a clinically validated option to meet this substantial need.
About Daré Bioscience
Founded with a mission to bridge the gap in women’s health, Daré Bioscience focuses on delivering credible, science-based solutions across a range of issues, including contraception, menopause, and sexual health. The company emphasizes rigorous clinical trials, peer-reviewed research, and adherence to cGMP standards to ensure effective products for women.
Looking Ahead
As part of its ongoing commitment to women’s health, Daré Bioscience continues to seek FDA approval for its proprietary sildenafil cream formulation. In the meantime, DARE to PLAY™ is available as a Section 503B compounded product, ensuring quality and safety through federally regulated manufacturing processes.
Get Involved
To learn more about DARE to PLAY™ and to find out how to access a prescription, visit daretoplaybio.com. Daré aims to expand availability to additional states throughout December and early 2026.